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Abstract. Long-term administration of glucocorticoid 
hormones is considered one of predominant pathological 
factors inducing osteonecrosis of the femoral head (ONFH) 
development and progression, in which reduction of blood 
supply leads to a progressive bone loss and impairment of 
bone structure in the majority of cases. In a non-hematopoietic 
system, erythropoietin (EPO) can stimulate angiogenesis and 
bone regeneration. However, the specific mechanism under-
lying the role of EPO in ONFH remains to be elucidated. 
Therefore, the purpose of this study was to determine the 
effect of EPO on the prevention of bone loss in ONFH. Male 
C57BL/6J mice 3 months old were divided into two groups: 
EPO group and control groups. ONFH was established by 
the administration prednisolone (PDS, 100 mg/kg) with 
co-treatment of lipopolysaccharide (LPS, 1 mg/kg). ONFH 
mice received recombinant mouse EPO (500 U/kg/day) or 
saline intramuscularly. The mice were sacrificed at 2, 4, 6 and 
8 weeks following the initiation of treatment. Alterations in the 
general architecture and histomorphology of the right femoral 
head were determined by hematoxylin and eosin staining and 
micro computed tomography (micro-CT). The expression 
of runt-related transcription factor 2 (Runx2), osteocalcin, 
vascular endothelial growth factor (VEGF) and platelet 
endothelial cell adhesion molecule (CD31) in the femoral head 
was tested by immunohistochemistry. Terminal deoxynucleo-
tidyl-transferase-mediated dUTP nick end labeling (TUNEL) 
assay was performed to detect apoptosis in femoral heads. 
Micro-CT data revealed that EPO significantly improved 
bone volume/total volume and bone mineral density following 
6 and 8 weeks of treatment. Histological analysis further 
demonstrated that EPO treatment improved the arrangement 
of trabeculae, thinning of trabeculae and other fractures in 
femoral heads, especially following 6 and 8 weeks of treat-
ment. Immunohistochemical analysis suggested that EPO 
treatment up-regulated the expressions of Runx2, osteocalcin, 
VEGF and CD31 at 4 and 8 weeks. The TUNEL apoptosis 
assay suggested that EPO intervention reduced apoptosis in 
avascular ONFH. Therefore, EPO prevents bone loss in ONFH 
in mice through enhancing Runx2-mediated osteogenesis, 
VEGF-mediated angiogenesis and inhibition of cell apoptosis.
Introduction
Osteonecrosis of the femoral head (ONFH) is a common and 
progressive disease that predominantly impairs the femoral 
head (1). With the development of the pathological process, it 
often progresses and leads to the collapse of the femoral head 
and osteoarthritis. Late stages of ONFH cause severe pain and 
require surgical arthrodesis, which severely affects the quality 
of life and the ability to work, and simultaneously causes 
economic burden for patients and society. Although multiple 
factors have been demonstrated to contribute to ONFN, 
long-term administration of glucocorticoid hormones (GCs) 
is considered a predominant cause. Currently, surgery is the 
primary treatment option, which can markedly improve the 
symptoms among young and middle-age patients. However, 
multiple revision surgeries are frequently required during the 
lifetime of the patient. Therefore, there is a need to develop 
novel medical therapies for the treatment of ONFH.
Erythropoietin (EPO), a pleiotropic cytokine mainly 
secreted by kidneys, stimulates the production of red blood 
cells (2). Previous studies reported beneficial effects of EPO 
on the non-hematopoietic system and on the bone fracture 
repair process, including stimulation of angiogenesis and bone 
formation (3,4). Moreover, Bakhshi et al (5) hypothesized that 
local administration of recombinant human erythropoietin 
(rhEPO) combined with core decompression surgery can 
enhance angiogenesis and bone regeneration in the early 
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stages of ONFH. However, the mechanism underlying the role 
of EPO on ONFH remain to be elucidated.
The pathomechanism underlying avascular necrosis of the 
femoral head induced by steroids can be ultimately ascribed to 
the damage of the local vasculature and restriction of oxygen 
supply to the femoral head (6). Vascularization in bone tissue 
supplies nutrients for the normal metabolic process, and angio-
genesis is essential for bone tissue regeneration in the necrotic 
area of the femoral head. Vascular endothelial growth factor 
(VEGF) regulates the coupling of angiogenesis and bone 
formation, and regeneration (7). It has been demonstrated 
that EPO serves an important role in capillary vessel forma-
tion and up-regulation of VEGF mRNA expression during 
tendon repair (8). In addition, studies have demonstrated that 
GCs can induce apoptosis of osteoblasts or osteocytes in the 
steroid-induced ONFH (9,10).
Therefore, the authors of the present study hypothesized that 
the administration of EPO prevents bone loss in a mouse model 
of ONFH by increasing osteocalcin- and vascular endothelial 
growth factor (VEGF)-mediated angiogenesis, up-regulating 
runt-related transcription factor 2 (Runx2)-mediated osteo-
genesis and inhibiting cell apoptosis.
Materials and methods
Animals. In the present study, male C57BL/6J mice (weight, 
23.5‑29.4 g; age, 3 months; n=80) were provided by the 
Center of Experimental Animals, Zhejiang Chinese Medical 
University (Hangzhou, China). Mice were kept in a tempera-
ture‑ and humidity‑controlled environment (22±1˚C, 40‑60% 
humidity, atmospheric CO2) with a free access to standard 
pellet food and tap water and a 12-h light/dark cycle. The 
present study was approved by the local Governmental Animal 
Care Committee (Hangzhou, China) and all the experimental 
procedures adhered to the guidelines set by the Center of 
Experimental Animals, Zhejiang Chinese Medical University 
(Hangzhou, China).
Model of ONFH. The model of ONFH was established to study 
the effect of EPO treatment on ONFH. Mice were randomly and 
equally divided into 2 groups: The EPO group and the control 
group. The mouse model of ONFH was established by the 
administration of prednisolone (PDS; Reyon Pharmaceutical 
Co., Ltd., Seoul, Korea) and co-treatment with lipopolysac-
charide (LPS; Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany), as previously described (11). Intraperitoneal (ip) 
administration of LPS (1 mg/kg) was immediately followed 
by an intramuscular injection of PDS (100 mg/kg). A second 
double-injection was performed 1 week following the initial 
co-injection of PDS/LPS and injections were continued every 
3 days until the mice were sacrificed. The mice in the control 
group were treated with the same dosing regimen, using saline 
as a substitute for LPS and PDS.
Intervention. Mice in the EPO group were intramuscularly 
administered recombinant mouse EPO (500 U/kg/day; cat. 
no. 959-ME-010; R&D Systems, Inc., Minneapolis, MN, 
USA) daily starting 1 week following the initial co-injection of 
PDS/LPS. The mice in the control group were administered an 
equivalent amount of saline. At 2, 4, 6 and 8 weeks following 
intervention, 6 mice from each group were sacrificed by 
carbon dioxide (CO2) narcosis. Subsequently, the mice were 
dissected and right femurs were harvested. Following removal 
of the skin and muscle from the legs, the entire femur with 
the hip joint was removed from the mouse's body by cutting 
above the hip joint and in the knee joint. Then the hip joint 
was dissected to expose the femoral head and remove the 
acetabular tissue. This tissue was used for micro computed 
tomography (micro-CT) and histological analyses.
Micro‑CT analysis. Micro-CT was performed using a Skyscan 
1172X‑ray microtomograph (resolution, 2.47 µm; Bruker 
Corporation, Billerica, MA, USA). Femurs were placed verti-
cally in the microtomograph sample holder and images were 
captured at 65 kV (153 µA) using a 0.5‑mm aluminum filter. A 
series of 483 projection images was captured with a rotation 
step of 0.40˚ between each image for each specimen. For each 
sample, 3-dimensional projection images were reconstructed 
from a stack of 2-dimensional images, using the NRecon 
software (version 1.6.10; Skyscan; Bruker Corporation). In the 
trabecular region of the femoral head, a 0.8x0.8 mm3 region of 
interest (ROI) was selected in the center of the femoral head 
using a semiautomatic contouring method, and the contouring 
of images was performed every 50 axial slices (proximal to 
distal). Bone morphometric parameters of ROI, including 
tissue volume (TV), bone volume (BV) and bone mineral 
density (BMD), were calculated using CTAn analysis software 
(version 1.15; Skyscan; Bruker Corporation), as previously 
described (12).
Histological analysis. Following harvesting of right femoral 
heads, samples were fixed with 10% buffered formalin for 
3 days and then decalcified in 14% ethylenediamine tetraacetic 
acid for 2 weeks. Decalcified samples were embedded in 
paraffin and 3 µm sections were prepared for histological 
analysis through haematoxylin and eosin (H&E) staining. The 
sections were stained in CAT hematoxylin (no. CATHE-MM; 
Biocare Medical, LLC, Pacheco, CA, USA) for 1 min and coun-
terstained in alcoholic-eosin (no. 17372-87-1; Sigma-Aldrich; 
Merck KGaA) for 1 min. All the procedures were performed at 
room temperature. Successful induction of ONFH was defined 
as diffuse presence of empty lacunae or pyknotic nuclei of 
bone cells in the trabecular bone, accompanied by surrounding 
bone marrow cell necrosis (13,14). Histopathological changes 
of ONFH were examined under a light microscope (Axio 
Scope A1; Carl Zeiss AG, Oberkochen, Germany) in a blinded 
manner by three independent investigators. At least 50 lacunae 
in each field were counted and 5 fields in each slide were 
selected randomly. The fraction of empty lacunae to total 
lacunae was defined as the ratio of empty lacuna number to the 
total lacuna number. The trabecular bone volume in the area 
of femoral heads was measured by Image-Pro Plus software 
(version, 6.0; Media Cybernetics, Inc., Rockville, MD, USA) 
and the percentage of trabecular BV/TV of femoral heads was 
calculated.
Immunohistochemical analysis. To investigate the expression 
levels of Runx2, osteocalcin, VEGF and platelet endothe-
lial cell adhesion molecule (CD31) in femoral heads, bone 
sections were prepared for immunohistochemistry. Following 
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deparaffinization in xylene and rehydration in a descending 
ethanol series (two changes in 100% ethanol, two changes 
in 95% ethanol, one change in 70% ethanol, and finally in 
distilled water), endogenous peroxidase was quenched by 3% 
hydrogen peroxide (H2O2) for 20 min, and antigen retrieval was 
performed using 0.01 M citrate buffer [(pH 6.0), 20 min, 95˚C; 
cat. no. C02-02001; Bioss, Beijing, China]. Following blocking 
of non‑specific binding sites with a normal goat serum (1:20; 
cat. no. C-0005; Bioss) for 20 min at room temperature, sections 
were incubated overnight with mouse monoclonal anti-Runx2 
(Cbfa1; 1:100; cat. no. D130-3; MBL International Co., Woburn, 
MA, USA), rabbit polyclonal anti‑osteocalcin (1 µg/ml; cat. 
no. M173; Takara Biotechnology Co., Ltd., Dalian, China), 
mouse monoclonal anti-VEGF (VG-1; 1:100; cat. no. ab1316; 
Abcam, Cambridge, UK) and rabbit polyclonal anti-CD31 
(1:50; cat. no. ARG52748; Arigo Biolaboratories, Hsinchu 
City, Taiwan) primary antibodies. Peroxidase-conjugated 
goat anti-mouse (1:100; cat. no. HA1006; Hangzhou HuAan 
Biotechnology Co., Ltd., Hangzhou, China) or peroxi-
dase-conjugated goat anti-rabbit (1:1,000; cat. no. GS1001; 
Shanghai Good-Science Biotech Company, Shanghai, China) 
immunoglobulin G antibodies were used as secondary 
antibodies, respectively. Diaminobenzidine (DAB) served 
as a chromogen, and hematoxylin served as a counterstain 
(20 sec, at room temperature). Tissue sections were examined 
under a light microscope (Zeiss Axio Scope A1, Carl Zeiss 
Co, Ltd). A total of 4 randomly‑selected fields from at least 
3 different tissue sections were selected for positive staining 
quantification. The mean optical density defined as the ratio 
of integrated optical density (IOD) to the corresponding cavity 
area was calculated using Image-Pro Plus software.
In order to further investigate angiogenesis, the analysis 
of microvessel density (MVD) based on CD31-positive 
staining was performed, as previously described (15). Slides 
were examined (magnification, x200) to identify the highest 
neovascularization area (hot spot) and a count of individual 
microvessels was conducted (magnification, x400). The 
brown-staining single endothelial cells or cell clusters that 
visibly separated from adjacent microvessels were defined as a 
countable microvessels. The MVD was calculated in five repre-
sentative areas of each slide. The evaluation was performed in 
a blinded manner by three independent investigators.
Terminal deoxynucleotidyl‑transferase‑mediated dUTP nick 
end labeling (TUNEL) assay. TUNEL assay was performed 
on bone sections using an ApopTag Plus Peroxidase In Situ 
Apoptosis kit (cat. no. S7101; EMD Millipore, Billerica, MA, 
USA) according to the manufacturer's protocol. Sections 
were deparaffinized, pretreated with proteinase K (20 µg/ml; 
cat. no. 21627; EMD Millipore) and endogenous peroxidase 
was quenched using H2O2 (3%). Bone sections were incu-
bated with a TdT enzyme (part#90418 from ApopTag Plus 
Peroxidase In Situ Apoptosis kit; EMD Millipore), visualized 
with DAB detection system (5 min at room temperature) and 
counterstained in 0.5% (w/v) methyl green (10 min at room 
temperature). Stained sections were visualized under a light 
microscope (Zeiss Axio Scope A1, Carl Zeiss Co., Ltd.). 
Four randomly‑selected fields from at least 3 different tissue 
sections were selected for positive staining quantification and 
the apoptosis rate (number of TUNEL-positive cells/number 
of all cells) was calculated in each section in a blinded manner 
by three independent investigators.
Statistical analysis. All data are presented as the 
mean ± standard deviation. Following the verification of 
normality of distributions and equal variance, comparisons 
between groups were performed by Student's t-test. Statistics 
were performed using SPSS software (version 13.0; SPSS 
Inc., Chicago, IL, USA). P<0.05 was considered to indicate a 
statistically significant difference.
Results
EPO treatment improves the microstructure of the femoral 
head in ONFH. The micro-CT analysis from a 3-dimensional 
reconstruction demonstrated that bone trabeculae of femoral 
heads were more finely spread and intact in the EPO group 
compared with the control group (Fig. 1A-J). Trabeculae grad-
ually lost their regular structure and connectivity in the control 
group. On the contrary, subchondral trabeculae in the EPO 
group maintained their normal structure and gradually recov-
ered at 4, 6 and 8 weeks. The quantitative analysis of micro‑CT 
parameters, including BV/TV and BMD, confirmed that the 
microstructure of subchondral trabeculae in femoral heads 
from the EPO group were improved compared with the control 
group following 6 and 8 weeks of treatment (Fig. 1K and L). 
In particular, the BV/TV ratio and BMD of femoral heads at 
6 and 8 weeks demonstrated significant differences between 
the two groups of interest (P<0.05; Fig. 1K and L). However, 
BV/TV and BMD did not differ significantly at 2 and 4 weeks 
following the EPO or saline treatment. These results suggest 
that prolonged administration of EPO can prevent bone loss of 
the femoral head in ONFH.
EPO treatment reduces the rate of empty lacunae and 
improves the trabecular bone volume in ONFH. As presented 
in Fig. 2, histological analysis of the H&E staining revealed 
severely thinned and disordered trabeculae, large empty bone 
lacunae and numerous pyknotic nuclei of osteocytes in the 
femoral heads from the control group, which indicated that an 
animal model of ONFH was successfully established (Fig. 2A, 
C, E and G). In contrast, the histological analysis of femoral 
heads from the EPO group demonstrated that the microstruc-
ture of trabeculae gradually recovered (Fig. 2B, D, F and H). 
Consistent with the findings of the micro‑CT assay, histo-
logical analyses of femoral heads demonstrated that trabecular 
bone volume displayed an increasing trend in mice in the EPO 
treatment group. Statistical analyses were performed between 
groups at multiple time points. BV/TV at 6 and 8 weeks in the 
EPO group was increased compared with the control group 
at the respective time points (P<0.05; Fig. 2I). In addition, in 
the EPO group, BV/TV at 8 weeks was increased compared 
with at 2 weeks (P<0.05; Fig. 2I). Moreover, the proportion of 
empty bone lacunae at 2 and 4 weeks in the control group was 
higher than in the EPO group at corresponding time points 
(P<0.05; Fig. 2J). These data are consistent with the hypothesis 
that administration of EPO can prevent bone loss in ONFH.
EPO treatment promotes expression of Runx2, osteocalcin, 
VEGF and CD31 in ONFH. To further investigate the effect 
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of EPO on ONFH at 4 and 8 weeks following treatment with 
EPO, Runx2, osteocalcin, VEGF and CD31 were examined 
in the femoral heads by immunohistochemistry. The authors 
of the present study identified that positive signals for Runx2 
and osteocalcin were significantly higher in the EPO group 
than in the control group (P<0.05; Fig. 3). In addition, an 
increased abundance of VEGF-positive staining was observed 
predominantly in the bone marrow cavity of femoral heads 
from the EPO group compared with the control group (P<0.05; 
Fig. 4A‑E) and the abundance of CD31‑positive staining was 
increased in subchondral trabecular bone of necrotic femoral 
heads in the EPO group compared with the control group 
(Fig. 4F‑I). The analysis of MVD, based on CD31‑positive 
staining, demonstrated that few microvessels were present in 
subchondral trabecular bones of necrotic femoral heads in the 
control group at 4 and 8 weeks, while the number of microves-
sels in the EPO group increased significantly (P<0.05; 
Fig. 4J). These data suggest that EPO can prevent bone loss in 
ONFH through enhancing Runx2-mediated osteogenesis and 
VEGF-mediated angiogenesis.
EPO treatment inhibits apoptosis induced by ONFH. At 4 and 
8 weeks following treatment with EPO, TUNEL assays were 
performed to verify whether administration of EPO affected 
apoptosis associated with ONFH. It was determined that the 
treatment with EPO led to decreased abundance of apoptotic 
cells, both in the trabecular bone and bone marrow cavity at 
the same time points (Fig. 5A-D). In addition, quantitative 
analysis confirmed a significantly increased apoptosis rate 
in the control group compared with the EPO group at 4 and 
8 weeks (P<0.05; Fig. 5E). These results suggest that the 
administration of EPO can inhibit apoptosis in the trabecular 
bone and bone marrow cavity in ONFH.
Discussion
ONFH is a multifactorial disease and a leading cause of 
mobility impairment. Long-term administration of GCs 
is considered one of the predominant pathological factors 
stimulating ONFH development and progression, leading to 
disruption of femoral head blood supply in the majority of 
cases. Resulting insufficient blood supply further affects the 
femoral head and eventually leads to its collapse and the devel-
opment of hip osteoarthritis in patients (16). At present, there 
are no effective treatments for ONFH and the current therapy 
focuses on the management of symptoms. Hip replacement 
is the only effective treatment of choice. Therefore, there is a 
need for alternative interventions to treat ONFH and reduce 
patient morbidity and economic impact.
In previous studies, angiogenic and growth factors demon-
strated promising effects on bone formation and regeneration 
in ONFH, including VEGF, fibroblast growth factors and 
hepatocyte growth factor (17-19). Several angiogenic factors 
could in theory be used for clinical treatment, but they could 
Figure 1. Micro‑CT analysis of the trabeculae of femoral heads. At 2 weeks, the (A) control, (B) EPO, (C) control and (D) EPO groups. At 4 weeks, the 
(E) control and (F) EPO groups. At 6 weeks, the (G) control and (H) EPO groups. At 8 weeks, the (I) control and (J) EPO groups. The trabecular bone in the 
EPO treatment group recovered gradually compared with the control group. (K) Quantitative analysis of the bone volume; and (L) bone mineral density in 
the control and EPO treatment group at 2, 4, 6 and 8 weeks. The BV/TV and BMD of femoral heads increased in the EPO treatment group at 6 and 8 weeks 
compared with the control group. Data are presented as the mean ± standard deviation. *P<0.05 vs. the control group. EPO, erythropoietin; BV/TV, bone 
volume/total volume; BMD, bone mineral density; micro-CT, micro computed tomography.
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also induce severe complications, including an increased 
intraosseous pressure due to vascular permeability, and arterial 
obliteration due to vascular smooth muscle proliferation (19). 
EPO is one of the most suitable candidates for the treatment 
of ONFH since it promotes bone regeneration (3,4) and has 
been clinically used for the treatment of chronic anemia with 
few side effects (20). However, it has been demonstrated that 
systemic administration of EPO can deteriorate blood supply 
and blood viscosity as it increases RBC mass, and induces 
hypertension and thromboembolic events (21). In addition, a 
previous study reported that administration of 5,000 U/kg/day 
EPO can significantly increase the hematocrit, which can 
aggravate ONFH through impaired blood flow and nutrition 
and perfusion (22). In order to avoid these complications, the 
authors of the present study decided to intramuscularly admin-
ister 500 U/kg/day EPO. During the experimental period, no 
systemic side effects were observed.
Results from Micro-CT and histological analyses clearly 
demonstrated that administration of EPO restored microstruc-
ture of the femoral head by improving the trabecular bone 
volume and reducing the rate of empty lacunae in ONFH. 
These observations are consistent with other studies which 
demonstrated that EPO treatment can enhance bone regenera-
tion (5). Therefore, EPO treatment can improve ONFH in mice.
In order to further elucidate the mechanism under-
lying EPO-induced stimulation of bone formation in vivo, 
immunohistochemical analysis of Runx2 and osteocalcin 
was performed. Runx2 is a key transcription factor associ-
ated with osteoblast differentiation, and osteocalcin is a 
biochemical marker secreted by mature osteoblasts (23). 
Immunohistochemistry of femoral heads indicated that EPO 
treatment up-regulated the expression of Runx2 and osteo-
calcin at 4 and 8 weeks. These results suggest that EPO may 
stimulate bone formation through Runx2-mediated osteo-
genesis. Other beneficial effects of EPO treatment include 
increased VEGF‑associated angiogenesis (4). As a significant 
component of skeletal development and repair, angiogenesis 
contributes to the process of bone development and repair 
through adequate formation of new capillaries from existing 
vessels (24). In addition, GCs inhibit the expression of VEGF 
in femoral heads and consequently limit angiogenesis and 
osteogenesis in ONFH induced by GCs (7). Experiments 
in vitro demonstrated that primary osteoblasts derived from 
clinically osteoarthritic femoral heads displayed downregula-
tion of VEGF following co‑incubation with GCs for 24 h (25). 
In the present study, immunohistochemical analysis of VEGF 
demonstrated that the expression VEGF can be upregulated 
in the femoral heads in ONFH following treatment with EPO, 
compared with the control group. CD31, a member of the Ig 
superfamily of cell adhesion molecules, is commonly used 
to indicate the presence of endothelial cells (26). An analysis 
of MVD was performed based on CD31-positive staining 
Figure 2. Histopathological analysis of the trabecular bone in the femoral head. At 2 weeks, the (A) control, (B) EPO, (C) control and (D) EPO groups. At 
4 weeks, the (E) control and (F) EPO groups. At 6 weeks, the (G) control and (H) EPO groups. At 8 weeks, the (I) control and (J) EPO groups. Severely 
thinned and disordered trabeculae, large empty bone lacunae and numerous pyknotic nuclei of osteocytes were evident in femoral heads from the control 
group, whereas the morphological structure of EPO treatment group relatively improved (magnification, x400). (I) Quantitative analysis of bone volume; and 
(J) empty lacunae rate in the control and EPO treatment group at 2, 4, 6 and 8 weeks. The BV/TV of femoral heads increased in the EPO treatment group at 6 
and 8 weeks compared with the control group. The empty lacunae rate in femoral heads decreased in the EPO treatment group at 2 and 4 weeks compared with 
the control group. Data are presented as the mean ± standard deviation. *P<0.05 vs. the control group. EPO, erythropoietin; BV/TV, bone volume/total volume.
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in femoral heads and it was demonstrated that microvessels 
were increased in the subchondral trabecular bone of necrotic 
femoral heads following treatment with EPO for 4 and 8 weeks, 
compared with the control group. Taken together, admin-
istration of EPO prevented bone loss in ONFH partially by 
increasing VEGF-mediated angiogenesis. It has been reported 
that VEGF is important for bone remodeling and regenera-
tion as it effectively couples angiogenesis and osteogenesis in 
the bone microenvironment (27), but whether EPO-induced 
osteogenesis is coupled with VEGF remains to be elucidated.
Apoptosis of osteoblasts and osteocytes is a common 
pathogenic pathway of GC-induced ONFH (28). A previous 
study suggested that apoptosis partially causes cell death in 
the femoral head of patients with ONFH (29). In addition, 
O'Brien et al (30) reported that GCs could directly induce 
apoptosis of osteoblasts and osteocytes. Moreover, once the 
blood supply from collateral circulation is restricted without 
enough capillary arterialization in GC-induced ONFH, the 
lack of available oxygen and nutrients may cause apoptosis of 
osteoblasts and osteocytes (31). Results of the TUNEL assay 
performed in the present study demonstrated that apoptosis 
occurred in osteocytes and bone marrow cells in the mice 
model of ONFH, while the apoptosis index in the EPO 
treatment group was significantly reduced at 4 and 8 weeks, 
suggesting that EPO could interfere with apoptosis and prevent 
bone loss in steroid-associated ONFH.
In conclusion, the present study demonstrated that the 
administration of EPO prevents bone loss by up-regulation of 
Runx2-mediated osteogenesis, an increase in VEGF-mediated 
angiogenesis and inhibition of cell apoptosis in the ONFH 
mouse model. Therefore, EPO is a promising agent for 
the treatment of ONFH. Further research will elucidate 
the mechanism underlying the effect of EPO treatment on 
the prevention of bone loss during ONFH while avoiding 
induction of side effects.
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group. EPO, erythropoietin; Runx2, runt-related transcription factor 2; OD, optical density.
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Figure 4. Immunohistochemical staining of VEGF and CD31 in of the femoral heads. For VEGF, the (A) control and (B) EPO groups at 4 weeks, and the 
(C) control and (D) EPO groups at 8 weeks. (E) Quantification of VEGF expression. For CD31, the (F) control and (G) EPO groups at 4 weeks, and the 
(H) control and (I) EPO groups at 8 weeks. (J) Quantification of CD31 expression levels. The mean density of VEGF in the EPO treatment group was higher 
than that in the control group at 4 and 8 weeks. MVD in the EPO treatment group significantly increased compared with the control group at 4 and 8 weeks. 
Data are presented as the mean ± standard deviation. *P<0.05 vs. the control group. VEGF, vascular endothelial growth factor; CD31, platelet endothelial cell 
adhesion molecule; EPO, erythropoietin; MVD, microvessel density.
Figure 5. Terminal deoxynucleotidyl‑transferase‑mediated dUTP nick end labeling assays of femoral heads. The (A) control and (B) EPO groups at 4 weeks; 
the (C) control and (D) EPO groups at 8 weeks. At 4 and 8 weeks following treatment with EPO, less apoptotic cells were present in the trabecular bone and 
bone marrow cavity of the EPO group compared with the control group. The black arrow indicates an apoptotic cell in the trabecular bone and the red arrow 
indicates apoptotic cells in the bone marrow cavity. (E) Quantitative analysis of the apoptosis rate in the control and EPO treatment group at 4 and 8 weeks. 
A significantly higher apoptosis rate was observed in the control group compared with the EPO treatment group at 4 and 8 weeks. Data were presented as the 
mean ± standard deviation. *P<0.05 vs. the control group. EPO, erythropoietin.
XU et al:  EPO PREVENTS BONE LOSS IN ONFH IN MICE8762
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